Canaccord Genuity Starts Akari Therapeutics (AKTX) at Buy
Tweet
Share
E-mailGet Alerts AKTX Hot Sheet
Price: $9.10 +15.63%
Rating Summary:
7 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 4 | Down: 20 | New: 18
Rating Summary:
7 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 4 | Down: 20 | New: 18
Join SI Premium – FREE
Canaccord Genuity initiated coverage on Akari Therapeutics (NASDAQ: AKTX) with a Buy rating and a price target of $33.00.
For an analyst ratings summary and ratings history on Akari Therapeutics click here. For more ratings news on Akari Therapeutics click here.
Shares of Akari Therapeutics closed at $16.36 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Starts CNB Financial Corp (CCNE) at Outperform
- Texas Capital Securities Starts CNO Financial Group (CNO) at Buy
- Stifel Starts Yellow Cake Plc. (YCA:LN) (YLLXF) at Buy
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageRelated Entities
Canaccord GenuitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
